ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1391

Associations Between Autoantibodies in Systemic Sclerosis and Cancer in a National Registry

Selma Lazizi1, Marie Hudson2, Murray Baron3, Marvin Fritzler4 and Sabrina Hoa5, 1Université de Montréal, Montreal, QC, Canada, 2Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, 3Jewish General Hospital, Montreal, QC, Canada, 4Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 5Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada

Meeting: ACR Convergence 2020

Keywords: Autoantibody(ies), Comorbidity, registry, Scleroderma, Systemic, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Autoantibodies are useful in systemic sclerosis (SSc) for predicting disease course. Some autoantibodies have been associated with a close temporal relationship with cancer. We investigated the association between SSc-specific and SSc-associated autoantibodies and cancer in a national registry.

Methods: Subjects recruited between 2004 and 2019 in a national SSc registry were studied (96% fulfill 2013 ACR/EULAR SSc classification criteria). The exposure was presence of SSc-specific/associated autoantibodies, namely anti-centromere (ACA), -topoisomerase I (ATA), -RNA polymerase 3 (ARNAP), -fibrillarin, -Th/To, -PM-Scl, -Ku, -U1RNP, -NOR90, -Ro52, -RNPC3 and -BICD2. The primary outcome was cancer-associated SSc, defined as cancer occurring within 2, 3 and 5 years of first non-Raynaud SSc manifestation. Univariate logistic regression was used to compare the odds of cancer-associated SSc between the autoantibody subgroups, using anti-centromere as reference. Descriptive statistics were used to compare clinical characteristics of subjects with cancer to those without cancer.

Results: Out of 1698 SSc subjects, 1474 (86.8%) had at least partially available autoantibody data. Mean (SD) age was 55.3 (12.3) years, 87% were female and 59% had a smoking history. Table 1 shows baseline characteristics stratified by autoantibodies. Cancer was diagnosed in 231 (13.6%) subjects. Median (IQR) time between cancer and disease onset was 7.0 (-0.7 to 16.4) years.

Table 2 shows the prevalence of cancer diagnosed within 2, 3 and 5 years of SSc onset, stratified by autoantibodies. Among 207 cancer subjects with available time data, 27 (13.6%), 37 (17.9%) and 58 (28.0%) were diagnosed with cancer within 2, 3 and 5 years of SSc onset. The most frequent types of cancers diagnosed within 5 years were breast (n=13), non-melanoma skin (NMSC, n=12), cervical/uterine (n=9) and hematological (n=8) cancers.

Overall, among all SSc subjects, no autoantibody was predictive of cancer-associated SSc (Table 3). However, ATA-positive subjects were more likely to have a solid cancer excluding NMSC (OR 6.6, 95% CI 1.4-46.4), especially breast cancer (OR 7.9, 95% CI 1.0-159.2), within 2 years of SSc onset. The risk of cancer-associated SSc was not significantly increased among ARNAP-positive subjects, although for solid cancers excluding NMSC, the OR was 5.8 (95% CI 0.56-125.8). Furthermore, subjects positive for at least 3 autoantibodies were more likely to develop cancer within 5 years of SSc onset compared to subjects with 1 or 2 autoantibodies (OR 3.0, 95% CI 1.3-6.1). Subjects who developed cancer within two years of SSc onset were generally younger (51.8 vs 57.9 years) and more frequently had a history of smoking (72% vs 59%) and scleroderma renal crisis (11% vs 3%).

Conclusion: In this study, ATA and overlapping autoantibodies were predictive of cancer-associated SSc for solid cancers excluding NMSC. Breast cancer was the most frequent type of cancer detected within 5 years of first non-Raynaud manifestation. Autoantibodies may help guide the approach to cancer screening. Larger studies are needed to define the risk of cancer-associated SSc within rarer autoantibody subgroups.

Table 1. Baseline characteristics for all subjects and stratified by autoantibodies

Table 2. Time interval between cancer diagnosis and systemic sclerosis onset in all subjects and stratified by autoantibodies

Table 3. Univariate logistic regression analyses for the risk of cancer within 2, 3 and 5 years of systemic sclerosis onset according to autoantibody status


Disclosure: S. Lazizi, None; M. Hudson, None; M. Baron, None; M. Fritzler, Inova Diagnostics Inc, 5, 8, Werfen International, 5, 8; S. Hoa, None.

To cite this abstract in AMA style:

Lazizi S, Hudson M, Baron M, Fritzler M, Hoa S. Associations Between Autoantibodies in Systemic Sclerosis and Cancer in a National Registry [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/associations-between-autoantibodies-in-systemic-sclerosis-and-cancer-in-a-national-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-between-autoantibodies-in-systemic-sclerosis-and-cancer-in-a-national-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology